Menadione

(phytomenadione)

PreclinicalSmall molecule

Eli Lilly

Menadione is one of 13 small molecule programs targeting Calcification. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

CalcificationActive, not recruiting

CalcificationPreclinical

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Calcification

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

1 2

Zemplar

AbbVie

Approved

1 3

Rocaltrol

Jazz Pharmaceuticals

Approved

1 4

Xarelto

WWim Janssens

Approved

3 5

Coumadin

AAbbott

Approved

2 6

Fosamax

OOrganon and Co

Approved

2 7

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 8

Phoslo

VVifor Fresenius Medical Care Renal Pharma

Approved

2 9

Tums

Otsuka

Preclinical

1 10

Renagel

GGenzyme, a Sanofi Company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Calcification1 trial

Effects of Fhytomenadione on Coronary Artery Calcification of Hemodialysis Patients

Completed·IInstituto Mexicano del Seguro Social·N/A·NCT04247087·60 enrolled

Critically Ill Patients1 trial

Effect of Vitamin K in Critically Ill Patients

Completed·RRegion Skane··NCT03782025·52 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

MENADIONE

NDA NDA002139

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for phytomenadione. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — phytomenadione compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for phytomenadione. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA002139). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Eli Lilly

Menadione

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Calcification1 trial

Critically Ill Patients1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News